Profound Medical Corp (PRN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Profound Medical Corp (PRN) has a cash flow conversion efficiency ratio of -0.222x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-11.03 Million ≈ $-7.98 Million USD) by net assets (CA$49.73 Million ≈ $35.97 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Profound Medical Corp stock valuation for the company's overall valuation and market capitalisation.
Profound Medical Corp - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Profound Medical Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Profound Medical Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Profound Medical Corp ranked by their cash flow conversion efficiency. See Profound Medical Corp (PRN) cash flow to debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
RideNow Group, Inc.
NASDAQ:RDNW
|
0.000x |
|
AURORA EIENDOM NK 75
F:IL7
|
N/A |
|
Global Atomic Corp
TO:GLO
|
0.002x |
|
Crane Harbor Acquisition Corp. - Class A Ordinary Shares
NASDAQ:CHAC
|
-0.005x |
|
Ratnaveer Precision Engineering Ltd
NSE:RATNAVEER
|
-0.005x |
|
Udaipur Cement Works Limited
NSE:UDAICEMENT
|
0.038x |
|
Ultra Chip
TWO:3141
|
0.036x |
|
Paramount Communications Limited
NSE:PARACABLES
|
-0.072x |
Annual Cash Flow Conversion Efficiency for Profound Medical Corp (2012–2025)
The table below shows the annual cash flow conversion efficiency of Profound Medical Corp from 2012 to 2025. View Profound Medical Corp stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CA$66.31 Million ≈ $47.97 Million |
CA$-38.88 Million ≈ $-28.12 Million |
-0.586x | -51.03% |
| 2024-12-31 | CA$60.42 Million ≈ $43.71 Million |
CA$-23.45 Million ≈ $-16.97 Million |
-0.388x | +46.47% |
| 2023-12-31 | CA$31.18 Million ≈ $22.56 Million |
CA$-22.61 Million ≈ $-16.36 Million |
-0.725x | -46.16% |
| 2022-12-31 | CA$52.00 Million ≈ $37.62 Million |
CA$-25.80 Million ≈ $-18.66 Million |
-0.496x | -78.87% |
| 2021-12-31 | CA$80.62 Million ≈ $58.32 Million |
CA$-22.36 Million ≈ $-16.17 Million |
-0.277x | -31.24% |
| 2020-12-31 | CA$97.35 Million ≈ $70.42 Million |
CA$-20.57 Million ≈ $-14.88 Million |
-0.211x | +84.92% |
| 2019-12-31 | CA$14.29 Million ≈ $10.34 Million |
CA$-20.03 Million ≈ $-14.49 Million |
-1.402x | -104.03% |
| 2018-12-31 | CA$19.55 Million ≈ $14.14 Million |
CA$-13.43 Million ≈ $-9.72 Million |
-0.687x | +47.98% |
| 2017-12-31 | CA$11.25 Million ≈ $8.13 Million |
CA$-14.85 Million ≈ $-10.75 Million |
-1.321x | -0.54% |
| 2016-12-31 | CA$11.04 Million ≈ $7.98 Million |
CA$-14.50 Million ≈ $-10.49 Million |
-1.314x | -167.42% |
| 2015-12-31 | CA$10.06 Million ≈ $7.28 Million |
CA$-4.94 Million ≈ $-3.58 Million |
-0.491x | +76.65% |
| 2014-12-31 | CA$1.37 Million ≈ $989.71K |
CA$-2.88 Million ≈ $-2.08 Million |
-2.104x | -2071.09% |
| 2013-12-31 | CA$-29.95 Million ≈ $-21.67 Million |
CA$-3.20 Million ≈ $-2.31 Million |
0.107x | -43.52% |
| 2012-12-31 | CA$-16.17 Million ≈ $-11.70 Million |
CA$-3.06 Million ≈ $-2.21 Million |
0.189x | -- |
About Profound Medical Corp
Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedb… Read more